Categories AlphaGraphs, Earnings, Other Industries
Tiffany stock surges on upbeat Q1 results, better outlook
Jewelry maker Tiffany & Co. (TIF) reported a 53% jump in earnings in the first quarter, riding on a 15% rise in worldwide net sales, higher operating margin and lower effective tax rate. The company has also raised its sales and earnings guidance for the full year, sending shares surging 12.4% before the opening bell.
With sales increasing 15% to $1 billion, net earnings climbed 53% year-over-year to $142 million or $1.14 per share. Broad-based sales growth and comparable sales growth of 10% drove worldwide net sales higher. All jewelry categories including Jewelry Collections, Engagement Jewelry, and Designer Jewelry showed strong sales growth in the quarter.
The strongest growth was seen in Asia-Pacific, where sales improved 28% helped by increased retail sales in China and Korea. In Americas, sales rose 9% on the higher spending by local customers and foreign tourists.
In the first quarter, Tiffany opened one company-operated store and closed two. As on April 30, 2018, the company operates 314 stores, with 123 in the Americas, 87 in Asia-Pacific, 54 in Japan, 46 in Europe, and four in the UAE.
Looking ahead into fiscal 2018, the company raised its guidance for net sales and net earnings. Worldwide net sales are now expected to increase by a high-single-digit percentage over last year, compared to the previous estimate of mid-single-digit percentage. Tiffany lifted EPS outlook to $4.50 – $4.70 from the prior forecast of $4.25 – $4.45.
Additionally, Tiffany’s board of directors has approved a new share repurchase program that authorizes the buyback of up to $1 billion of its common stock. This new program, which expires on January 31, 2022, will replace its existing share repurchase program announced in January 2016.
Shares of Tiffany ended Tuesday’s regular trading session down 0.97% at $102.24 on the NYSE. The stock had been trading between $84.15 and $111.44 for the past 52 weeks.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on